Novartis Investigative Site

Morgantown, West Virginia 26506-9260

0 studies enrolling now · 15 studies all time

What they study most

Acute Heart Failure, Cancer, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Diabetic Macular Edema, Lymphoma, Follicular, Metastatic Renal Cell Carcinoma, Multiple Myeloma, Neoplasms, Breast, Neovascular Age-related Macular Degeneration, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma — Completed
• Rainbow Extension Study — Completed
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD — Completed
• Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy — Stopped early
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma — Completed
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed
• Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease — Completed
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed